Compare CALM & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CALM | AMRX |
|---|---|---|
| Founded | 1957 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.7B |
| IPO Year | 1996 | 2018 |
| Metric | CALM | AMRX |
|---|---|---|
| Price | $77.23 | $12.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $92.00 | $15.60 |
| AVG Volume (30 Days) | 922.3K | ★ 1.2M |
| Earning Date | 04-01-2026 | 05-01-2026 |
| Dividend Yield | ★ 10.85% | N/A |
| EPS Growth | ★ 338.49 | 157.89 |
| EPS | ★ 7.34 | 0.22 |
| Revenue | ★ $1,351,609,000.00 | N/A |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | $7.13 |
| P/E Ratio | ★ $10.44 | $58.95 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $71.92 | $7.02 |
| 52 Week High | $126.40 | $15.42 |
| Indicator | CALM | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 49.91 |
| Support Level | $76.78 | $12.50 |
| Resistance Level | $83.83 | $13.54 |
| Average True Range (ATR) | 2.49 | 0.46 |
| MACD | 0.21 | 0.09 |
| Stochastic Oscillator | 38.17 | 44.50 |
Cal-Maine Foods Inc produces and sells shell eggs. Its main market is the United States. The company's product portfolio contains nutritionally enhanced, cage-free, organic, and brown eggs. Cal-Maine Foods markets the shell eggs to a diverse group of customers, including grocery-store chains, club stores, and food service distributors. The company's brands are Egg-Land's, Land O' Lakes, Farmhouse, and 4-Grain. The Company has one reportable operating segment, which is the production, grading, packaging, marketing and distribution of shell eggs.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.